SRC and gastric cancer: The finding showed that ERK1/2 inhibitor (U0126), JNK1/2 inhibitor (SP600125) and Src inhibitor (PP2) significantly suppress IL‐8‐induced motility activity of gastric cancer cells (Fig. 2E).